From academic results to patient treatments: Hurdles to tackle
From academic results to patient treatments: Hurdles to tackle
Presenter: Stephen Minger | UPM Biomedicals 7th Annual Conference, 2021
Dr Stephen Minger is one of the pioneering researchers in human stem cell biology and regenerative medicine. He received his PhD in Pathology/Neurosciences in 1992 from the Albert Einstein College of Medicine. After post-doctoral work in gene therapy and neural stem cell biology at UCSD, he was appointed a Lecturer in Biomolecular Sciences at King's College London in 1998. He was appointed a Senior Lecturer in 2005 and was the Director of the Stem Cell Biology Laboratory from 2002- 2009. In 2009, he was appointed Global Director for R&D for Cell Technologies at GE Healthcare. In 2013, he was appointed Chief Scientist for GE Healthcare, where he was responsible for global research strategy in cell therapy, regenerative medicine, and precision diagnostics. He left full-time employment with GE in 2015 but continued as Senior Consultant for GE Healthcare until 2018.
Over the past 25+ years, Stephen’s has been at the forefront of human gene therapy/stem cell research. In 2002, he was awarded one of the first two licenses by the UK Human Fertilisation and Embryology Authority (HFEA) for the derivation of human embryonic stem cells. He was one of the first two groups to be granted a research license by the HFEA in 2008 to pursue Somatic Cell Nuclear Transfer to generate “hybrid human embryos”. He was actively involved with the UK Dept of Health in the consultation with the UK Parliament that led to the passage of the Human Embryo Bill of 2009. He was also a Member of the UK Gene Therapy Advisory Committee from 2006-2012.
Stephen is the Founder/Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for biotechnology companies and the investment community in gene/cell-based therapies, human tissue fabrication, implementation of robotics/synthetic intelligence, machine-brain interfaces, and human pluripotent stem cell technologies, amongst others.